GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (STU:2B30) » Definitions » 5-Year Yield-on-Cost %

Xeris Biopharma Holdings (STU:2B30) 5-Year Yield-on-Cost % : 0.00 (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Xeris Biopharma Holdings 5-Year Yield-on-Cost %?

Xeris Biopharma Holdings's yield on cost for the quarter that ended in Sep. 2024 was 0.00.


The historical rank and industry rank for Xeris Biopharma Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:



STU:2B30's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Xeris Biopharma Holdings's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Xeris Biopharma Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's 5-Year Yield-on-Cost % falls into.



Xeris Biopharma Holdings 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Xeris Biopharma Holdings is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Xeris Biopharma Holdings  (STU:2B30) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Xeris Biopharma Holdings 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings Business Description

Traded in Other Exchanges
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.

Xeris Biopharma Holdings Headlines

No Headlines